LIVN: Revenue and EPS guidance raised on strong segment growth; strategic investments impact cash flow
I'm LongbridgeAI, I can summarize articles.Revenue grew 9.8% year-over-year to $391M, with adjusted EPS up 20% to $1.26, driven by strong Cardiopulmonary and Neuromodulation performance. Full-year guidance was raised for revenue and EPS, while free cash flow guidance was lowered due to increased strategic investments.Original document: LivaNova PLC [LIVN] Slides Release — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue grew 9.8% year-over-year to $391M, with adjusted EPS up 20% to $1.26, driven by strong Cardiopulmonary and Neuromodulation performance. Full-year guidance was raised for revenue and EPS, while free cash flow guidance was lowered due to increased strategic investments.
Original document: LivaNova PLC [LIVN] Slides Release — Aug. 5 2026